Physicians' Academy for Cardiovascular Education

2021 ESC Guidelines reduce statin eligibility in low-ASCVD-risk European countries

Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines

Literature - Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG - JAMA Cardiol. 2022 Aug 1;7(8):836-843. doi: 10.1001/jamacardio.2022.1876

Introduction and methods

Background

Statin treatment is restricted to individuals who have a 10-year risk of ASCVD above certain clinical guideline–defined treatment thresholds [1]. The SCORE (Systematic Coronary Risk Evaluation) prediction model estimates the 10-year risk of fatal ASCVD events and has been used since the publication of the 2003 European Society of Cardiology (ESC) Guidelines on statin use [2]. This risk model was also used in the previous 2019 ESC/European Atherosclerosis Society (EAS) Guidelines on dyslipidemia [3].

The updated version of this risk model, the SCORE2 model, now estimates the 10-year risk of total (i.e. fatal and nonfatal) ASCVD events [4]. The SCORE2 model was incorporated in the 2021 ESC Guidelines on CVD prevention, as well as new age-specific treatment thresholds for statins [5 ]. Models assessing the 10-year risk of total ASCVD events are also recommended in the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline on assessment of CVD risk (pooled cohort equations (PCE) model) and the (in 2016 updated) UK National Institute for Health and Care Excellence (NICE) clinical guideline on lipid modification (QRISK model) [6,7].

Aim of the study

In apparently healthy individuals, the authors compared the clinical performance of the 2021 ESC Guidelines for CVD prevention on eligibility of primary prevention with statins with that of the 2013 ACC/AHA guideline, the 2016 NICE guideline, and the 2019 ESC/EAS Guidelines.

Methods

In this population-based, contemporary cohort study, data from 66,909 White Europeans from the Copenhagen General Population Study were used who were enrolled from 2003 through 2015. As the 2021 ESC Guidelines only provide class I recommendations for statin treatment for individuals aged 40–49 years with SCORE2 risk ≥7.5% and for those aged 50–69 years with SCORE2 risk ≥10%, people in this age range were included. Exclusion criteria were preexisting ASCVD, DM, CKD, and statin use. The mean follow-up time was 9.2 years.

In this study, the low-risk version of the SCORE2 model, which is intended for most of Western Europe, the low-risk version of the SCORE1 model, and the latest version of the QRISK model, QRISK3 [8], were used.

Outcomes

Calibration of the risk models (assessed with the predicted/observed (P/O) ratio), statin eligibility of the participants, and sensitivity and specificity of the models for ASCVD events according to the different guideline criteria were assessed.

Main results

Estimated 10-year risk

Risk model calibration and discrimination

Clinical performance of guidelines

Clinical performance of different SCORE2 treatment thresholds

Conclusion

Use of the new treatment thresholds in the 2021 ESC Guidelines, which are based on the SCORE2 prediction model, reduced an individual’s eligibility for primary prevention with statins to 4% in Denmark—a low-ASCVD-risk European country—compared with 20%–34% according to the ACC/AHA, NICE, and ESC/EAS Guidelines. Lowering the treatment thresholds could improve the clinical performance of the 2021 ESC Guidelines.

The authors believe their “results are important for clinical practice and future European-ESC [G]uidelines on primary prevention with statins, as they point toward a likely unintended dramatic reduction in the potential for ASCVD prevention by implementing the 2021 European-ESC age-specific treatment criteria.”

References

Show references

Find this article online at JAMA Cardiol.

Share this page with your colleagues and friends: